Skip to main content
Erschienen in: Tumor Biology 4/2014

01.04.2014 | Research Article

The association between polymorphism of P53 Codon72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3,704 cases

verfasst von: Surong Hu, Lianying Zhao, Jingting Yang, Miao Hu

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Emerging evidence has shown that p53gene participates in human carcinogenesis as tumor suppressors. Polymorphism of p53 gene codon72 arginine (Arg)/proline (Pro) (rs1042522) may influence the function of p53 protein and then affect the processing of carcinogenesis. It has been suggested that p53 codon72 Arg/Pro polymorphism is associated with susceptibility to hepatocellular carcinoma (HCC). However, published results are inconsistent and inconclusive. To examine the validity of the association between the polymorphism and HCC risk, we performed this meta-analysis. We have conducted a search of case–control studies on the associations of p53 codon72 polymorphism with susceptibility to HCC in PubMed, ScienceDirect, BioMed central, Springer, EBSCO, Wanfang databases, and Chinese National Knowledge Infrastructure databases. A total of 15 studies were identified with 3,704 cases and 4,559 controls for codon72 Arg/Pro polymorphism. The result did support a significant genetic association between Pro allele and susceptibility to HCC in all the genetic models. Similarly, subgroup analysis showed significant associations between the Arg/Pro polymorphism and susceptibility to HCC when stratifying by race, gender, source of controls, and hepatitis virus infection status. This meta-analysis suggests that p53 codon72 Arg/Pro polymorphism may be associated with the risk of HCC, especially in subgroup analysis of Asian and Caucasian population, hospital-based population, the female, and the individuals infected with hepatitis virus. However, well-designed studies based on different ethnic groups with larger sample size and more detailed data are needed to confirm these conclusions.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.PubMedCrossRef
2.
Zurück zum Zitat Pogribny IP, Rusyn I. Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett. 2014;342(2):223–30.PubMedCentralPubMedCrossRef Pogribny IP, Rusyn I. Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett. 2014;342(2):223–30.PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Dokianakis DN, Koumantaki E, Billiri K, Spandidos DA. P53 codon 72 polymorphism as a risk factor in the development of HPV-associated non-melanoma skin cancers in immunocompetent hosts. Int J Mol Med. 2000;5(4):405–9.PubMed Dokianakis DN, Koumantaki E, Billiri K, Spandidos DA. P53 codon 72 polymorphism as a risk factor in the development of HPV-associated non-melanoma skin cancers in immunocompetent hosts. Int J Mol Med. 2000;5(4):405–9.PubMed
5.
Zurück zum Zitat Pandith AA, Khan NP, Rashid N, Azad N, Zaroo I, Hafiz A, et al. Impact of codon 72 Arg > Pro single nucleotide polymorphism in TP53 gene in the risk of kangri cancer: a case control study in Kashmir. Tumour Biol. 2012;33(4):927–33.PubMedCrossRef Pandith AA, Khan NP, Rashid N, Azad N, Zaroo I, Hafiz A, et al. Impact of codon 72 Arg > Pro single nucleotide polymorphism in TP53 gene in the risk of kangri cancer: a case control study in Kashmir. Tumour Biol. 2012;33(4):927–33.PubMedCrossRef
6.
Zurück zum Zitat Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC. Tp53 and liver carcinogenesis. Hum Mutat. 21:201–16. Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC. Tp53 and liver carcinogenesis. Hum Mutat. 21:201–16.
7.
Zurück zum Zitat Dumont P, Leu JI, Della Pietra III AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33(3):357–65.PubMedCrossRef Dumont P, Leu JI, Della Pietra III AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33(3):357–65.PubMedCrossRef
8.
Zurück zum Zitat Son MS, Jang MJ, Jeon YJ, Kim WH, Kwon CI, Ko KH, et al. Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. Gene. 2013;524(2):156–60.PubMedCrossRef Son MS, Jang MJ, Jeon YJ, Kim WH, Kwon CI, Ko KH, et al. Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. Gene. 2013;524(2):156–60.PubMedCrossRef
9.
Zurück zum Zitat Mohana Devi S, Balachandar V, Arun M, Suresh Kumar S, Balamurali Krishnan B, Sasikala K. Analysis of genetic damage and gene polymorphism in hepatocellular carcinoma (HCC) patients in a South Indian population. Dig Dis Sci. 2013;58(3):759–67.PubMedCrossRef Mohana Devi S, Balachandar V, Arun M, Suresh Kumar S, Balamurali Krishnan B, Sasikala K. Analysis of genetic damage and gene polymorphism in hepatocellular carcinoma (HCC) patients in a South Indian population. Dig Dis Sci. 2013;58(3):759–67.PubMedCrossRef
10.
Zurück zum Zitat Ezzikouri S, El Feydi AE, Chafik A, Benazzouz M, El Kihal L, Afifi R, et al. The Pro variant of the p53 codon 72 polymorphism is associated with hepatocellular carcinoma in Moroccan population. Hepatol Res. 2007;37(9):748–54.PubMedCrossRef Ezzikouri S, El Feydi AE, Chafik A, Benazzouz M, El Kihal L, Afifi R, et al. The Pro variant of the p53 codon 72 polymorphism is associated with hepatocellular carcinoma in Moroccan population. Hepatol Res. 2007;37(9):748–54.PubMedCrossRef
11.
Zurück zum Zitat Sumbul AT, Akkiz H, Bayram S, Bekar A, Akgollu E, Sandikci M. P53 codon 72 polymorphism is associated with susceptibility to hepatocellular carcinoma in the Turkish population: a case–control study. Mol Biol Rep. 2012;39:1639–47.PubMedCrossRef Sumbul AT, Akkiz H, Bayram S, Bekar A, Akgollu E, Sandikci M. P53 codon 72 polymorphism is associated with susceptibility to hepatocellular carcinoma in the Turkish population: a case–control study. Mol Biol Rep. 2012;39:1639–47.PubMedCrossRef
12.
Zurück zum Zitat Xu Y, Liu L, Liu J, Zhang Y, Zhu J, Chen J, et al. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer. 2011;128(2):412–7.PubMedCrossRef Xu Y, Liu L, Liu J, Zhang Y, Zhu J, Chen J, et al. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer. 2011;128(2):412–7.PubMedCrossRef
13.
Zurück zum Zitat Yoon YJ, Chang HY, Ahn SH, Kim JK, Park YK, Kang DR, et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis. 2008;29(6):1192–6.PubMedCrossRef Yoon YJ, Chang HY, Ahn SH, Kim JK, Park YK, Kang DR, et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis. 2008;29(6):1192–6.PubMedCrossRef
14.
Zurück zum Zitat Zhu ZZ, Cong WM, Liu SF, Dong H, Zhu GS, Wu MC. Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. World J Gastroenterol. 2005;11(2):289–92.PubMed Zhu ZZ, Cong WM, Liu SF, Dong H, Zhu GS, Wu MC. Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. World J Gastroenterol. 2005;11(2):289–92.PubMed
15.
Zurück zum Zitat Anzola M, Cuevas N, López-Martínez M, Saiz A, Burgos JJ, de Pancorbo MM. Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett. 2003;193(2):199–205.PubMedCrossRef Anzola M, Cuevas N, López-Martínez M, Saiz A, Burgos JJ, de Pancorbo MM. Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett. 2003;193(2):199–205.PubMedCrossRef
16.
Zurück zum Zitat Yu MW, Yang SY, Chiu YH, Chiang YC, Liaw YF, Chen CJ. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology. 1999;29(3):697–702.PubMedCrossRef Yu MW, Yang SY, Chiu YH, Chiang YC, Liaw YF, Chen CJ. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology. 1999;29(3):697–702.PubMedCrossRef
17.
Zurück zum Zitat Leveri M, Gritti C, Rossi L, Zavaglia C, Civardi E, Mondelli MU. Codon 72 polymorphism of p53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. Cancer Lett. 208:75–79. Leveri M, Gritti C, Rossi L, Zavaglia C, Civardi E, Mondelli MU. Codon 72 polymorphism of p53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. Cancer Lett. 208:75–79.
18.
Zurück zum Zitat Di Vuolo V, Buonaguro L, Izzo F, Losito S, Botti G, Buonaguro FM, et al. TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infect Agent Cancer. 2011;6(13). Di Vuolo V, Buonaguro L, Izzo F, Losito S, Botti G, Buonaguro FM, et al. TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infect Agent Cancer. 2011;6(13).
19.
Zurück zum Zitat Mah YH, Hsu CS, Liu CH, Liu CJ, Lai MY, Chen PJ, et al. Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan. Hepatol Int. 2011;5(3):814–21.PubMedCrossRef Mah YH, Hsu CS, Liu CH, Liu CJ, Lai MY, Chen PJ, et al. Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan. Hepatol Int. 2011;5(3):814–21.PubMedCrossRef
20.
Zurück zum Zitat Yang Y, Xia T, Li N, Zhang J, Yang Y, Cong W, et al. Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma. Protein Cell. 2013;4(1):71–81.PubMedCrossRef Yang Y, Xia T, Li N, Zhang J, Yang Y, Cong W, et al. Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma. Protein Cell. 2013;4(1):71–81.PubMedCrossRef
21.
Zurück zum Zitat Peng TYL, Liu ZM, Shen HM, Ong CN, Peng MH, et al. Significant association of p53 codon 72 single nucleotide polymorphism with hepatocellular carcinoma in Guangxi population. Chin J Surg. 2004;42:313–4. Peng TYL, Liu ZM, Shen HM, Ong CN, Peng MH, et al. Significant association of p53 codon 72 single nucleotide polymorphism with hepatocellular carcinoma in Guangxi population. Chin J Surg. 2004;42:313–4.
22.
Zurück zum Zitat Zhang YYYH, Fan XJ. Association of p53 codon72 polymorphism and risk of hepatocellular carcinoma. J Chin Oncol. 2012;18:189–93. Zhang YYYH, Fan XJ. Association of p53 codon72 polymorphism and risk of hepatocellular carcinoma. J Chin Oncol. 2012;18:189–93.
23.
Zurück zum Zitat Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127(9):820-826 Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127(9):820-826
24.
25.
Zurück zum Zitat Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485–91.PubMedCentralPubMedCrossRef Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485–91.PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991;350(6317):429–31.PubMedCrossRef Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991;350(6317):429–31.PubMedCrossRef
27.
Zurück zum Zitat Sheen IS, Jeng KS, Wu JY. Is p53 gene mutation an indicator of the biological behaviors of recurrence of hepatocellular carcinoma? World J Gastroenterol. 2003;9(6):1202–7.PubMed Sheen IS, Jeng KS, Wu JY. Is p53 gene mutation an indicator of the biological behaviors of recurrence of hepatocellular carcinoma? World J Gastroenterol. 2003;9(6):1202–7.PubMed
28.
Zurück zum Zitat Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer. 2004;108(2):196–9.PubMedCrossRef Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer. 2004;108(2):196–9.PubMedCrossRef
29.
Zurück zum Zitat Siddique M, Sabapathy K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene. 2006;25(25):3489–500.PubMedCrossRef Siddique M, Sabapathy K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene. 2006;25(25):3489–500.PubMedCrossRef
30.
Zurück zum Zitat Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9(2):95–107.PubMedCrossRef Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9(2):95–107.PubMedCrossRef
31.
Zurück zum Zitat Chen X, Liu F, Li B, Wei YG, Yan LN, Wen TF. p53 codon 72 polymorphism and liver cancer susceptibility: a meta-analysis of epidemiologic studies. World J Gastroenterol. 2011;17(9):1211–8.PubMedCentralPubMedCrossRef Chen X, Liu F, Li B, Wei YG, Yan LN, Wen TF. p53 codon 72 polymorphism and liver cancer susceptibility: a meta-analysis of epidemiologic studies. World J Gastroenterol. 2011;17(9):1211–8.PubMedCentralPubMedCrossRef
32.
Zurück zum Zitat Ding C, Yu H, et al. Tp53 codon 72 polymorphism with hepatocellular carcinoma: a meta-analysis. J Int Med Res. 2012;40:446–54.PubMedCrossRef Ding C, Yu H, et al. Tp53 codon 72 polymorphism with hepatocellular carcinoma: a meta-analysis. J Int Med Res. 2012;40:446–54.PubMedCrossRef
33.
Zurück zum Zitat Lv L, Wang P, Zhou X, Sun B. Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk. Tumour Biol. 2013;34(3):1451–9.PubMedCrossRef Lv L, Wang P, Zhou X, Sun B. Association between the p53 codon 72 Arg/Pro polymorphism and hepatocellular carcinoma risk. Tumour Biol. 2013;34(3):1451–9.PubMedCrossRef
34.
Zurück zum Zitat Puente XS, Velasco G, Gutiérrez-Fernández A, Bertranpetit J, King MC, López-Otín C. Comparative analysis of cancer genes in the human and chimpanzee genomes. BMC Genomics;7(15). Puente XS, Velasco G, Gutiérrez-Fernández A, Bertranpetit J, King MC, López-Otín C. Comparative analysis of cancer genes in the human and chimpanzee genomes. BMC Genomics;7(15).
35.
Zurück zum Zitat Yeh SH, Chen PJ. Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology. 2010;78 Suppl 1:172–9.PubMedCrossRef Yeh SH, Chen PJ. Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology. 2010;78 Suppl 1:172–9.PubMedCrossRef
36.
Zurück zum Zitat Xu H, Wei Y, Zhang Y, Xu Y, Li F, Liu J, et al. Oestrogen attenuates tumour progression in hepatocellular carcinoma. J Pathol. 2012;228(2):216–29.PubMedCrossRef Xu H, Wei Y, Zhang Y, Xu Y, Li F, Liu J, et al. Oestrogen attenuates tumour progression in hepatocellular carcinoma. J Pathol. 2012;228(2):216–29.PubMedCrossRef
37.
Zurück zum Zitat Hussain SP, Schwank J, Staib F, Wang XW, Harris CC. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene. 2007;26(15):2166–76.PubMedCrossRef Hussain SP, Schwank J, Staib F, Wang XW, Harris CC. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene. 2007;26(15):2166–76.PubMedCrossRef
38.
Zurück zum Zitat Bréchot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology. 2004;127(5 Suppl 1):S56–61.PubMedCrossRef Bréchot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology. 2004;127(5 Suppl 1):S56–61.PubMedCrossRef
Metadaten
Titel
The association between polymorphism of P53 Codon72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3,704 cases
verfasst von
Surong Hu
Lianying Zhao
Jingting Yang
Miao Hu
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1483-7

Weitere Artikel der Ausgabe 4/2014

Tumor Biology 4/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.